论文部分内容阅读
皮质类固醇、脾切除和免疫抑制剂曾被应用于特发怀血小板减少性紫癜(ITP)的治疗。但是,某些病例对所有这些治疗均无反应。最近,Imbach等介绍一种对这些难治性病例特别有效的新疗法——大剂量r-球蛋白治疗,取得良好效果。本文探讨这种治疗对血小板计数增加的机理。病人和方法 ITP的诊断根据下列标准:血小板减少在3个月以上,骨髓巨核细胞正常或增加,无明显脾肿大,并除外已知发病因素引起的血小板减少。本文5例病人均给予免疫球蛋白“Veno-globulin-1”(日本绿十字有限公司产品),0.4g/kg/天,静脉注射,连续5天。测定抗血小板抗体效价、血小板相关IgG(PAIgG)和循环血中免疫复合物。
Corticosteroids, splenectomy and immunosuppressive agents have been used in the treatment of idiopathic thrombocytopenic purpura (ITP). However, some cases do not respond to all of these treatments. Recently, Imbach et al. Introduced a new treatment that is particularly effective in these refractory cases, high-dose r-globulin, with good results. This article explores the mechanism by which this treatment increases platelet count. Patients and Methods The diagnosis of ITP was based on the following criteria: Thrombocytopenia over 3 months, normal or increased bone marrow megakaryocytes, no obvious splenomegaly, with the exception of known thrombocytopenia due to disease factors. Five patients in this article were given immunoglobulin “Veno-globulin-1” (Japan Green Cross Co., Ltd.), 0.4g / kg / day, intravenously for 5 days. Antiplatelet antibody titers, platelet-associated IgG (PAIgG) and circulating blood immune complexes were determined.